Minerva Neurosciences Stock Forecast, Price & News

Minerva Neurosciences (NASDAQ:NERV) Frequently Asked Questions

Is Minerva Neurosciences a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Minerva Neurosciences stock.
View analyst ratings for Minerva Neurosciences or view top-rated stocks.

How has Minerva Neurosciences' stock price been impacted by Coronavirus?

Minerva Neurosciences' stock was trading at $6.36 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NERV shares have decreased by 86.9% and is now trading at $0.8349.
View which stocks have been most impacted by COVID-19.

Are investors shorting Minerva Neurosciences?

Minerva Neurosciences saw a decrease in short interest in the month of December. As of December 31st, there was short interest totaling 376,300 shares, a decrease of 19.8% from the December 15th total of 469,300 shares. Based on an average daily trading volume, of 508,600 shares, the days-to-cover ratio is currently 0.7 days. Approximately 0.9% of the shares of the company are short sold.
View Minerva Neurosciences' Short Interest.

When is Minerva Neurosciences' next earnings date?

Minerva Neurosciences is scheduled to release its next quarterly earnings announcement on Monday, March 14th 2022.
View our earnings forecast for Minerva Neurosciences.

How were Minerva Neurosciences' earnings last quarter?

Minerva Neurosciences, Inc. (NASDAQ:NERV) issued its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.22) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.22). During the same period last year, the company posted ($0.19) earnings per share.
View Minerva Neurosciences' earnings history.

What price target have analysts set for NERV?

2 equities research analysts have issued 12-month price targets for Minerva Neurosciences' stock. Their forecasts range from $3.00 to $10.00. On average, they expect Minerva Neurosciences' stock price to reach $6.50 in the next twelve months. This suggests a possible upside of 678.5% from the stock's current price.
View analysts' price targets for Minerva Neurosciences or view top-rated stocks among Wall Street analysts.

Who are Minerva Neurosciences' key executives?

Minerva Neurosciences' management team includes the following people:

• Rémy Henri Luthringer, Executive Chairman & Chief Executive Officer
• Geoff Race, President
• Joseph Reilly, Chief Operating Officer & Senior Vice President
• Fred Ahlholm, Chief Financial Officer & Senior VP-Finance
• Michael Davidson, Chief Medical Officer

Who are some of Minerva Neurosciences' key competitors?

Some companies that are related to Minerva Neurosciences include Tonix Pharmaceuticals (TNXP), Mustang Bio (MBIO), AVEO Pharmaceuticals (AVEO), BriaCell Therapeutics (BCTX), Clearside Biomedical (CLSD), NervGen Pharma (NGENF), RedHill Biopharma (RDHL), Immunome (IMNM), Actinium Pharmaceuticals (ATNM), Opiant Pharmaceuticals (OPNT), ProMetic Life Sciences (PFSCF), Infinity Pharmaceuticals (INFI), Daré Bioscience (DARE), Annovis Bio (ANVS) and Oasmia Pharmaceutical AB (publ) (OASMY).
View all of NERV's competitors.

What other stocks do shareholders of Minerva Neurosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), PTC Therapeutics (PTCT), Immunomedics (IMMU), VBI Vaccines (VBIV), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Moderna (MRNA), T2 Biosystems (TTOO) and Advanced Micro Devices (AMD).

What is Minerva Neurosciences' stock symbol?

Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."

How do I buy shares of Minerva Neurosciences?

Shares of NERV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Minerva Neurosciences' stock price today?

One share of NERV stock can currently be purchased for approximately $0.83.

How much money does Minerva Neurosciences make?

Minerva Neurosciences has a market capitalization of $35.67 million and generates $41.18 million in revenue each year. The biopharmaceutical company earns $1.94 million in net income (profit) each year or ($0.85) on an earnings per share basis.

How many employees does Minerva Neurosciences have?

Minerva Neurosciences employs 11 workers across the globe.

What is Minerva Neurosciences' official website?

The official website for Minerva Neurosciences is www.minervaneurosciences.com.

Where are Minerva Neurosciences' headquarters?

Minerva Neurosciences is headquartered at 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451.

How can I contact Minerva Neurosciences?

Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at (617) 600-7373 or via email at [email protected].